TIGIT and triple-negative breast carcinoma: In triple-negative breast cancer, the TIGIT/CD155 pathway was also found to inhibit PI3K, p-AKT, and p-mTOR expression, reducing glucose uptake and lactic acid production in CD8+ T cells, leading to CD8+ T cell activation and impairment of effector functions in the tumor microenvironment.